Abstract
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Williams, M., Walker, K., Turkes, A. et al. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53, 629–636 (1986). https://doi.org/10.1038/bjc.1986.106
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.106
This article is cited by
-
A Review on the Metabolism of 25 Peptide Drugs
International Journal of Peptide Research and Therapeutics (2021)
-
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
British Journal of Cancer (2004)
-
Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts
British Journal of Cancer (1999)